15.01.2007 – 08:30

Intercell AG

Intercell completes acquisition of Pelias

Wien (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.

» 100 % of Pelias shares acquired in an all-share
deal; former shareholders of Pelias receive 349,815 new Intercell
shares from capital increase » Intercell’s product portfolio
strengthened by clinical stage Pseudomonas vaccine candidate ¬ -
focus on expanding Intercell’s leading position as technology
provider and vaccine developer in the field of hospital-acquired
infections

Intercell AG (VSE; "ICLL") announced today that the acquisition of
Pelias Biomedical Development AG, Vienna (Austria) was completed with
a capital increase. 349.815 new shares, which represent about 0.9
percent of Intercell’s current share capital, were issued to the
former Pelias shareholders in return for transferring their Pelias
shares to Intercell. The transaction had been announced in an ad-hoc
statement on December 6, 2006.

The 349,815 new shares start trading at the Vienna Stock Exchange on
January 17, 2006. After completion of the capital increase,
Intercell’s total number of shares issued amounts to 39,881,712.

Pelias will remain a separate legal entity operating as a subsidiary
of Intercell AG. Pelias develops products and holds certain licenses
in the field of vaccines against important pathogens involved in
hospital-acquired infections, including a clinical stage Pseudomonas
vaccine candidate and a number of antigens, which have been
identified by Intercell’s proprietary Antigen Identification Program
(AIP®). Hospital-acquired infections are one of the major causes of
death and serious illness worldwide and result in an annual burden of
USD 20 billion in the developed world.

About hospital-acquired infections

Nosocomial infections - or hospital acquired infections - are
bacterial or fungal infections which are acquired in a hospital
setting and cause a variety of severe infections, many
life-threatening such as pneumonia, sepsis and bacteremia.  Each
year, around 2 million infections and 100,000 deaths occur in the US
alone due to nosocomial infections. The annual burden to the society
is constantly increasing due to the antibiotics resistance of the
most problematic bacteria. In the field of S. aureus infections
Intercell has a strong strategic alliance with Merck & Co., Inc. with
a vaccine product in clinical trials.

About Intercell AG:

Intercell AG is a biotechnology company focused on the research,
development, manufacturing and future commercialization of innovative
vaccines for the prevention and treatment of infectious diseases, for
which there exists a substantial unaddressed medical need. Intercell
develops antigens and immunizers (adjuvants), which are derived from
its proprietary technology platforms and has in-house GMP
manufacturing capability. Intercell has strategic partnerships with a
number of global pharmaceutical companies, including Novartis, Wyeth,
Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and
the Statens Serum Institut. Intercell has a broad development
pipeline with a vaccine product candidate for Japanese Encephalitis
in Phase III clinical trials, a vaccine product candidate for
Hepatitis C in Phase II, partnered vaccine candidates for
Tuberculosis and S. aureus, which are in Phase I, and more than five
other product candidates focused on infectious diseases in
pre-clinical development. Intercell is listed on the Vienna stock
exchange under the symbol "ICLL". For more information please visit:
www.intercell.com

end of announcement                               euro adhoc 15.01.2007 08:29:00

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market